FDA Cites New Zealand Firm for Multiple Violations

Drug GMP Report
A A
The FDA observed multiple deficiencies related to equipment and quality control during a November inspection of Douglas Manufacturing’s finished drug facility in Lincoln, Auckland.

To View This Article:

Login

Subscribe To Drug GMP Report